
## Martin L Miller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8694606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science, 2015, 348, 124-128.	12.6	6,756
2	The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 2013, 45, 1113-1120.	21.4	6,265
3	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
4	Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis. Science Signaling, 2010, 3, ra3.	3.6	1,319
5	Emerging landscape of oncogenic signatures across human cancers. Nature Genetics, 2013, 45, 1127-1133.	21.4	1,190
6	Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nature Biotechnology, 2009, 27, 549-555.	17.5	470
7	Linear Motif Atlas for Phosphorylation-Dependent Signaling. Science Signaling, 2008, 1, ra2.	3.6	418
8	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	28.9	368
9	KinomeXplorer: an integrated platform for kinome biology studies. Nature Methods, 2014, 11, 603-604.	19.0	304
10	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell, 2019, 179, 219-235.e21.	28.9	270
11	Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	21.4	136
12	Perturbation Biology: Inferring Signaling Networks in Cellular Systems. PLoS Computational Biology, 2013, 9, e1003290.	3.2	128
13	NetPhosYeast: prediction of protein phosphorylation sites in yeast. Bioinformatics, 2007, 23, 895-897.	4.1	121
14	Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods. Cancer Research, 2019, 79, 6238-6246.	0.9	116
15	Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 2021, 124, 1759-1776.	6.4	113
16	The SH2 Domain Interaction Landscape. Cell Reports, 2013, 3, 1293-1305.	6.4	110
17	Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets. Science Signaling, 2013, 6, ra85.	3.6	97
18	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Systems, 2015, 1, 197-209.	6.2	94

MARTIN L MILLER

#	Article	IF	CITATIONS
19	NetPhosBac – A predictor for Ser/Thr phosphorylation sites in bacterial proteins. Proteomics, 2009, 9, 116-125.	2.2	67
20	Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. Cancer Discovery, 2016, 6, 1148-1165.	9.4	62
21	Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nature Genetics, 2019, 51, 1741-1748.	21.4	59
22	Cell-selective labeling using amino acid precursors for proteomic studies of multicellular environments. Nature Methods, 2013, 10, 768-773.	19.0	55
23	Centriolar satellites are acentriolar assemblies of centrosomal proteins. EMBO Journal, 2019, 38, e101082.	7.8	55
24	Kinase-Specific Prediction of Protein Phosphorylation Sites. Methods in Molecular Biology, 2009, 527, 299-310.	0.9	52
25	Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8+ T Cell Priming To Promote Memory Formation and Metabolic Readiness. Journal of Immunology, 2015, 194, 2089-2098.	0.8	39
26	Meta-analysis of heterogeneous data sources for genome-scale identification of risk genes in complex phenotypes. Genetic Epidemiology, 2011, 35, 318-332.	1.3	31
27	Characterization and location of secretory phospholipase A2 groups IIE, V, and X in the rat brain. Journal of Neuroscience Research, 2006, 83, 874-882.	2.9	26
28	Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers. Clinical Cancer Research, 2018, 24, 5133-5142.	7.0	26
29	Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases. Nature Communications, 2020, 11, 4306.	12.8	26
30	Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers, 2020, 12, 3403.	3.7	24
31	Spatial Normalization of Reverse Phase Protein Array Data. PLoS ONE, 2014, 9, e97213.	2.5	23
32	MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer. Nucleic Acids Research, 2016, 44, D986-D991.	14.5	21
33	Motif Decomposition of the Phosphotyrosine Proteome Reveals a New N-terminal Binding Motif for SHIP2. Molecular and Cellular Proteomics, 2008, 7, 181-192.	3.8	15
34	Copy number aberrations drive kinase rewiring, leading to genetic vulnerabilities in cancer. Cell Reports, 2021, 35, 109155.	6.4	10
35	Ovarian tumors orchestrate distinct cellular compositions. Immunity, 2021, 54, 1107-1109.	14.3	9